Although pediatricians have long recognized that respiratory syncytial virus (RSV) is the
single most important cause of lower respiratory tract infection (LRTI) in infants and young …

Background Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality
among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The …

Background The cost-effectiveness of immunisation strategies with a long-acting
monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for …

Monoclonal antibodies (mABs) are safe and effective proteins produced in laboratory that
may be used to target a single epitope of a highly conserved protein of a virus or a bacterial …

Respiratory syncytial virus (RSV) is a leading cause of hospitalization and infant mortality
worldwide. There are currently no approved vaccines against RSV, and immunoprophylaxis …

Objectives Model-based cost-effectiveness analyses on maternal vaccine (MV) and
monoclonal antibody (mAb) interventions against respiratory syncytial virus (RSV) use …

Background Bronchiolitis is a major cause of hospitalization in infants, particularly in the first
six months of life, with approximately 60–80% of admissions due to respiratory syncytial …

Soon after the discovery that respiratory syncytial virus (RSV) was the major cause of
bronchiolitis in infants, in 1956 [1], vaccines were developed to try and prevent both infection …

Novel RSV immunizations hold promise to reduce the RSV burden in infants, with
substantial impact on everyday practice. Tailored parental guidance will be instrumental for …

Setting The study enrolled participants in the northern hemisphere in 2019 (150 sites in 20
countries) and the southern hemisphere in 2020 (10 sites in 1 country). Patient enrollment …